BROMAZEPAM
Stage III Prostate Cancer AJCC v8
Fred Hutchinson Cancer CenterSmall moleculePhase 1Active
CC
40/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 25/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Stage III Prostate Cancer AJCC v8 cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Osimertinib OHSU Knight Cancer Institute | Phase 2 | CCC |
Sor-C13 M.D. Anderson Cancer Center | Phase 1 | CC |
AZD 8186 National Cancer Institute (NCI) | Phase 1 | CC |
Bendamustine Fred Hutchinson Cancer Center | Phase 1 | CC |
T-Cell Receptor-Engineered T-Cells Fred Hutchinson Cancer Center | Phase 1 | CC |
Edicotinib M.D. Anderson Cancer Center | Phase 1 | C |
Same molecule, other indications
BROMAZEPAM is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →